RPS26B Antibody

What is RPS26 and what makes it a significant research target?

RPS26 (ribosomal protein S26) is a component of the small (40S) ribosomal subunit with a reported length of 115 amino acid residues and a molecular weight of approximately 13 kDa in humans. It belongs to the Eukaryotic ribosomal protein eS26 protein family and is primarily localized in the endoplasmic reticulum and cytoplasm .

The significance of RPS26 in research stems from several factors:

• It plays an essential role in ribosome biogenesis, specifically in the maturation of 40S ribosomal subunits

• Mutations in the RPS26 gene are found in 5.3-11.6% of Diamond-Blackfan anemia (DBA) cases, making it one of the most frequently mutated genes in this inherited bone marrow failure syndrome

• Unlike other ribosomal proteins affected in DBA, RPS26 displays unique properties including a potential ability to dissociate from mature 40S subunits, giving rise to specialized ribosomes with distinct translation capabilities

• Interestingly, no RPS26-mutated DBA patient has developed myelodysplastic syndrome or cancer, suggesting possible protective mechanisms that warrant further investigation

What applications are RPS26 antibodies commonly used for?

RPS26 antibodies are utilized in various experimental techniques for detecting and studying the protein. According to available research data, the primary applications include:

The versatility of these applications allows researchers to investigate RPS26 expression, localization, interactions, and functional characteristics in various experimental contexts .

What tissues and cell types show positive reactivity with RPS26 antibodies?

Based on validated experimental data, RPS26 antibodies have demonstrated positive reactivity in multiple tissues and cell types:

When designing experiments, researchers should note that antigen retrieval conditions can significantly impact detection success. For instance, when performing IHC on human breast cancer or kidney tissue, TE buffer at pH 9.0 is recommended for optimal results, with citrate buffer at pH 6.0 as an alternative method .

How does RPS26 deficiency affect erythroid differentiation and development?

RPS26 deficiency significantly impairs erythroid differentiation, as demonstrated through experimental models using HUDEP-1 cells (a human erythroid progenitor cell line expressing fetal hemoglobin). When RPS26 is silenced in these cells:

• Expression of key erythroid markers is altered, including:

  • Reduced levels of erythroid-specific transcripts (EPOR, GATA1, and SOX6)

  • Decreased expression of surface markers like CD71 and GlyA

  • Lower globin protein levels

• The pattern of impairment appears similar to what has been observed in models with deficiencies of other ribosomal proteins implicated in DBA, particularly RPS19

• The effect suggests that RPS26 deficiency either blocks or delays the maturation process of erythroid cells, consistent with the early-onset anemia observed in DBA patients

Notably, these findings align with the clinical presentation of Diamond-Blackfan anemia, where patients typically present with severe anemia within the first few months of life, with a median diagnosis age of 2-3 months .

What is the relationship between RPS26 and Diamond-Blackfan anemia (DBA)?

RPS26 plays a significant role in the pathogenesis of Diamond-Blackfan anemia through several interconnected mechanisms:

• Prevalence: Mutations in the RPS26 gene account for 5.3-11.6% of DBA cases, making it one of the most commonly mutated genes in this disorder

• Pathophysiology: As with other ribosomal proteins affected in DBA, RPS26 deficiency disrupts ribosome biogenesis, specifically impairing the maturation of 40S ribosomal subunits

• Phenotypic features: DBA patients with RPS26 mutations present with:

  • Red cell aplasia

  • Congenital malformations

  • A distinctive lack of myelodysplastic syndrome or cancer development, unlike patients with mutations in other RP genes

• Molecular mechanism: Research using RPS26-silenced HUDEP-1 cells has demonstrated that RPS26 deficiency impairs erythroid differentiation, affecting:

  • Expression of erythroid transcription factors

  • Surface marker profiles

  • Globin protein synthesis

• Translational implications: The unique properties of RPS26 may contribute to specialized translation patterns that potentially protect against malignant transformation, suggesting it might serve as a promising therapeutic target

Experimental models using HUDEP-1 cells with RPS26 knockdown provide valuable insights into these mechanisms, offering advantages over patient-derived samples which are scarce and difficult to obtain for research purposes .

What unique properties distinguish RPS26 from other ribosomal proteins affected in DBA?

RPS26 exhibits several distinctive characteristics that set it apart from other ribosomal proteins implicated in Diamond-Blackfan anemia:

• Dynamic association with ribosomes: Unlike most ribosomal proteins, RPS26 can dissociate from mature 40S subunits under certain stress conditions (demonstrated in yeast models), creating a population of RPS26-deficient ribosomes with altered translation properties

• Stress-responsive behavior: In yeast, stresses such as high Na+ or H+ concentrations trigger the release of Rps26 from ribosomes through interaction with the chaperone Tsr2

• Specialized translation: Ribosomes lacking RPS26 preferentially translate specific mRNAs involved in stress-response pathways until conditions normalize and RPS26 is reincorporated

• Cancer protection: Notably, no RPS26-mutated DBA patient has developed myelodysplastic syndrome or cancer, in contrast to patients with mutations in other ribosomal protein genes. This suggests that RPS26-deficient ribosomes may selectively translate subsets of mRNAs with protective functions against cancer development

While these mechanisms have been well-characterized in yeast, the existence of specialized ribosomes lacking RPS26 in human cells requires further investigation. The HUDEP-1 cell model with RPS26 silencing represents a valuable tool for exploring these unique properties in a human erythroid context .

What are the optimal experimental conditions for RPS26 antibody applications?

To achieve optimal results with RPS26 antibodies across different applications, researchers should consider the following evidence-based parameters:

Western Blot (WB):

• Recommended dilution: 1:500-1:2000

• Expected molecular weight: While calculated at 13 kDa, RPS26 typically appears at 18-21 kDa on immunoblots

• Positive control tissues: Mouse ovary and lung tissues have demonstrated consistent detection

Immunohistochemistry (IHC):

• Recommended dilution: 1:20-1:200

• Antigen retrieval: TE buffer at pH 9.0 (primary recommendation) or citrate buffer at pH 6.0 (alternative)

• Validated tissues: Human breast cancer and kidney tissues

Immunofluorescence (IF)/Immunocytochemistry (ICC):

• Recommended dilution: 1:20-1:200

• Validated cell lines: MCF-7 cells

Immunoprecipitation (IP):

• Antibody amount: 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate

• Validated sample: Mouse lung tissue

Storage and Handling:

• Storage temperature: -20°C (unconjugated antibodies)

• Buffer conditions: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Stability: Typically 12 months from receipt date; 6 months at 2-8°C after reconstitution

• Note: Avoid repeated freeze-thaw cycles

For all applications, it is recommended to titrate the antibody in each specific testing system to determine optimal conditions for the particular experimental setup .

How can researchers validate the specificity of RPS26 antibodies?

Ensuring antibody specificity is crucial for generating reliable research data. For RPS26 antibodies, the following validation approaches are recommended:

1. Multiple detection techniques:
Confirm consistent results across different applications (e.g., WB, IHC, IF) as RPS26 antibodies have been validated in multiple techniques

Molecular weight verification:

• Expected calculation: 13 kDa

• Observed range: 18-21 kDa in Western blot analysis

• Note: The discrepancy between calculated and observed weights is common for ribosomal proteins due to post-translational modifications

Knockdown/knockout validation:

• Use RPS26 siRNA (particularly siRNA S26-B and C which have shown ~50% reduction in protein levels)

• Compare antibody signal in control versus RPS26-silenced samples

• Published literature includes KD/KO validation for certain RPS26 antibodies

Cross-reactivity assessment:

• Test across multiple species if working with non-human models

• Validated antibodies have demonstrated reactivity with human, mouse, and rat samples

Positive and negative controls:

• Positive tissue controls: Mouse ovary, mouse lung, human breast cancer, human kidney

• Positive cell line control: MCF-7 cells

• Negative control: Omit primary antibody while maintaining all other experimental conditions

Epitope analysis:

• Consider the immunogen used to generate the antibody

• Some RPS26 antibodies use fusion protein antigens (e.g., Ag6706, Ag6718)

Following these validation steps helps ensure that experimental results genuinely reflect RPS26 biology rather than non-specific or off-target effects.

What experimental design considerations are important when studying RPS26 in erythroid differentiation models?

When investigating RPS26 function in erythroid differentiation using models like HUDEP-1 cells, researchers should consider these critical experimental design factors:

Knockdown efficiency optimization:

• Multiple siRNA targets should be tested to identify those providing optimal silencing

• Based on published research, siRNA S26-B and C achieved approximately 50% reduction in RPS26 protein levels, mimicking the haploinsufficiency observed in DBA patients

• Validate knockdown at both mRNA (qRT-PCR) and protein (Western blot) levels

Appropriate timeline for differentiation experiments:

• For HUDEP-1 cells, culture in differentiation medium (DM) for at least 2 days to observe increased expression of erythroid markers

• Collect data at multiple timepoints to capture the dynamics of differentiation impairment

Comprehensive marker panel for erythroid differentiation:

• Transcription factors: EPOR, GATA1, SOX6 (marker of definitive erythropoiesis)

• Surface markers: CD71 (transferrin receptor), GlyA (glycophorin A)

• Protein expression: Globin levels

• These markers have demonstrated significant changes during normal differentiation and with RPS26 silencing

Statistical analysis considerations:

• When working with small sample sizes (N = 3-6 biological replicates), non-parametric tests like the Mann-Whitney test are recommended over tests assuming Gaussian distribution

• Consider p ≤ 0.05 as the threshold for statistical significance

Comparison with other ribosomal protein deficiencies:

• Include RPS19-deficient models as comparators when possible, as these represent the most well-studied DBA models

• This comparison helps identify both common pathways and unique effects of RPS26 deficiency

These considerations help ensure that experiments investigating RPS26 function in erythroid differentiation produce reliable, reproducible, and physiologically relevant results.